التفاصيل البيبلوغرافية
| العنوان: |
Treatment, outcome and re-vaccination of patients with SARS-CoV-2 vaccine-associated immune thrombocytopenia. |
| المؤلفون: |
Ruzicka, Michael, Wurm, Sonja, Lindner, Lars, Dreyling, Martin, von Bergwelt-Baildon, Michael, Boeck, Stefan, Giessen-Jung, Clemens, Milani, Valeria, Stemmler, Joachim H., Subklewe, Marion, Weigert, Oliver, Spiekermann, Karsten |
| المصدر: |
Infection; Feb2023, Vol. 51 Issue 1, p231-238, 8p, 3 Charts, 2 Graphs |
| مصطلحات موضوعية: |
PREVENTION of infectious disease transmission, PATIENT aftercare, PROTHROMBIN time, PNEUMONIA, IMMUNIZATION, COVID-19, HOSPITAL emergency services, BLOOD vessels, PREDNISOLONE, COVID-19 vaccines, DISEASE vectors, DEXAMETHASONE, THROMBOPENIC purpura, CELL receptors, JOINT pain, VITAMIN C, TREATMENT effectiveness, SEVERITY of illness index, MESSENGER RNA, PLATELET count, DESCRIPTIVE statistics, FIBRINOGEN, LACTATE dehydrogenase, ASPIRIN, RESEARCH funding, BLOOD cell count, FATIGUE (Physiology), HEADACHE, COMPUTED tomography, DATA analysis software, HEMORRHAGE, FIBRIN fibrinogen degradation products |
| مصطلحات جغرافية: |
GERMANY |
| مستخلص: |
Purpose: Following the emergency use authorization of BNT162b2 by the Food and Drug administration (FDA) in early December 2020, mRNA- and vector-based vaccines became an important means of reducing the spread and mortality of the COVID-19 pandemic. The European Medicines Agency labelled immune thrombocytopenia (ITP) as a rare adverse reaction of unknown frequency after vector-, but not mRNA-vaccination. Here, we report on the long-term outcome of 6 patients who were diagnosed with de-novo, vaccine-associated ITP (VA-ITP), and on the outcome of subsequent SARS-CoV-2 re-vaccinations. Methods: Patients were included after presenting to our emergency department. Therapy was applied according to ITP guidelines. Follow-up data were obtained from outpatient departments. Both mRNA- or vector-based vaccines were each used in 3 cases, respectively. Results: In all patients, the onset of symptoms occurred after the 1st dose of vaccine was applied. 5 patients required treatment, 3 of them 2nd line therapy. All patients showed a complete response eventually. After up to 359 days of follow-up, 2 patients were still under 2nd line therapy with thrombopoietin receptor agonists. 5 patients have been re-vaccinated with up to 3 consecutive doses of SARS-CoV-2 vaccines, 4 of them showing stable platelet counts hereafter. Conclusion: Thrombocytopenia after COVID-19 vaccination should trigger a diagnostic workup to exclude vaccine-induced immune thrombotic thrombocytopenia (VITT) and, if confirmed, VA-ITP should be treated according to current ITP guidelines. Re-vaccination of patients seems feasible under close monitoring of blood counts and using a vaccine that differs from the one triggering the initial episode of VA-ITP. [ABSTRACT FROM AUTHOR] |
|
Copyright of Infection is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
